



**THE FOUNDATION
FOR SECURE
MARKETS®**

#59883

Date: October 01, 2026

Subject: Arbutus Biopharma Corporation - Settlement Update
Option Symbol: ABUS
Date: 10/01/2026
* * * Effective Immediately * * *

Effective on September 25, 2026, settlement of ABUS options exercise/assignment activity was subject to broker to broker settlement (see OCC Information Memo #59837). ABUS shares (CUSIP 03879J100) are now eligible for Continuous Net Settlement ("CNS") at the National Securities Clearing Corporation ("NSCC"). As a result, all exercise and assignment activity for ABUS options as of October 1, 2026 and thereafter for ABUS options will no longer be subject to broker to broker settlement and will settle through NSCC.

Any existing broker to broker obligations on ABUS exercise and assignment from September 25, 2026 through September 30, 2026 will remain subject to broker to broker settlement.

The deliverable for ABUS options will remain the underlying 100 Arbutus Biopharma Corporation Common Shares.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and futures and the nature of any adjustment is made by OCC pursuant to Chapter 28 (XXVIII) of OCC's Rules. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com.

Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.